8
1.0 CSL Behring: Longstanding
Commitment to the HAE Community
1.1 CSL Behring: Biotherapies for Life
™
•
Other critical care therapies, such as concentrates of
fibrinogen, prothrombin complex, albumin, and
streptokinase
•
Bleeding disorder therapies, such as factor VIII and IX
concentrates, von Willebrand factor/factor VIII complex,
and desmopressin
•
Immunoglobulin products that include more than a
dozen therapies, such as normal intravenous and sub-
cutaneous therapies as well as anti-Rhesus factor D
and other hyperimmune immunoglobulins
•
Wound-healing therapies, including fibrin sealant
and factor XIII concentrate
•
Pulmonary therapy for the treatment of alpha-1-
proteinase inhibitor deficiency (genetic emphysema).
CSL Behring is a biotherapies company dedicated to
improving the quality of life for people who have rare
and serious diseases. Its global leadership in the plasma
protein biotherapeutics industry qualifies CSL Behring to
offer products and services that enhance the quality of
life and support the community of patients, healthcare
professionals, patient associations, and others whose
lives are touched by medical conditions such as hereditary
angioedema (HAE).
With a passion for providing life-enhancing and lifesaving
therapies, a commitment to cultivating a promising product
pipeline, and an emphasis on continual improvement, CSL
Behring researches, develops, manufactures, and markets
a vast array of therapies. These include:
•
Berinert
®
(pasteurized, virus filtered (nanofiltered) C1
esterase inhibitor [pnfC1-INH]) for the treatment of
acute episodes of HAE and pre-procedure prevention
(short-term prophylaxis e.g. before medical procedures)
Chapter 1 Highlights
•
CSL Behring is passionate about improving
the quality of life for people with rare
diseases.
•
CSL Behring has a long and distinguished
history that dates back to the late 19
th
century. CSL Behring products meet the
highest standards for safety and quality
currently in place.
•
CSL Behring is dedicated to research
and committed to continually improving
treatment options for patients with
rare diseases.
•
CSL Behring is committed to providing
education, services, and other resources
to patients and families affected by HAE
and to the healthcare professionals who
serve them.
